Cancer touches all New Zealanders in some way, and the number of cancer diagnoses is on the rise, with one in three of us likely to be diagnosed in our lifetime.
Giving hope in the fight to beat cancer, new immunotherapy medicines are emerging with better survival data than we've seen before. Yet, because of New Zealand's strict system for funding, many of these essential new medicines are not currently available to all who need them.
As New Zealanders, we should be challenging the new government to ensure cancer is seen as a priority, not only in terms of faster access to specialists and treatment, but also faster access to the most effective medicines. Patients may be getting diagnosed more quickly, but in many cases they are being given treatments that have been superseded in most other countries.
Medsafe is one of the best agencies in the world at registering new medicines. Medsafe's appraisal and approval timelines are consistent with other global regulators, such as the European and Australian agencies.
However, New Zealand is the only OECD country with a capped pharmaceutical budget, and while Pharmac does its best within the existing budget, the trade-off is lack of access to new medicines. A study by Professor Frank Lichtenberg noted that between 2006 and 2010 about 12 per cent of deaths from cancer within five years from diagnosis would have been avoided if cancer survival in New Zealand was the same as Australia.